Literature DB >> 12459319

Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma.

Reyna Sánchez1, Ana Laura Espinosa-de-los-Monteros, Victoria Mendoza, Eduardo Brea, Irma Hernández, Ernesto Sosa, Moisés Mercado.   

Abstract

BACKGROUND: In the follow-up of patients with well-differentiated thyroid carcinomas (WTC), a thyroid-stimulating hormone (TSH) >or=30 micro U/mL is generally accepted as adequate to perform whole body scans (WBS), determine thyroglobulin (Tg), and administer radioiodine therapeutically. These patients, inevitably rendered hypothyroid, are traditionally switched to T3 for 3-4 weeks prior to withdrawing all thyroid hormones for an additional 2-3 weeks. Neither TSH and Tg elevation dynamics nor WBS characteristics after simply interrupting L-T4 treatment without T3 administration have been evaluated.
METHODS: TSH, total T4 and T3, as well as FT4 were measured weekly after discontinuing L-T4 in 21 subjects (group I) and after thyroidectomy in 10 subjects (group II). WBS and Tg determination was performed upon achievement of TSH >or=30 micro U/mL.
RESULTS: By the second week, 42% of group I patients and 70% of group II patients had TSH >or=30 micro U/mL. By the third week, 90% in group I and 100% in group II had achieved this target. Group I patients who needed 4 weeks to increase TSH received a greater cumulative radioiodine dose and had higher Tg levels. Positive WBS were found in eight cases and the incidence of a negative WBS with elevated Tg was significantly higher when evaluation occurred at the second week of L-T4 withdrawal compared to the fourth week.
CONCLUSIONS: L-T4 interruption is a reasonable alternative to temporary T3 in preparation for radioiodine scanning and treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459319     DOI: 10.1016/s0188-4409(02)00394-6

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  6 in total

1.  Age and the thyrotropin response to hypothyroxinemia.

Authors:  Rebecca Over; Sonia Mannan; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

2.  In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.

Authors:  Laticia A Valle; Revital L Gorodeski Baskin; Kyle Porter; Jennifer A Sipos; Raheela Khawaja; Matthew D Ringel; Richard T Kloos
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

3.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

4.  Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer.

Authors:  Daiki Kayano; Junichi Taki; Anri Inaki; Hiroshi Wakabayashi; Ayane Nakamura; Makoto Fukuoka; Seigo Kinuya
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013

5.  Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?

Authors:  Zekiye Hasbek; Bülent Turgut
Journal:  Mol Imaging Radionucl Ther       Date:  2016-06-05

6.  Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma.

Authors:  Yushen Gu; Hongrong Xu; Yanling Yang; Yan Xiu; Pengcheng Hu; Min Liu; Xiangqing Wang; Jun Song; Yan Di; Jian Wang; Xiaoxia Zhang; Tao Xu; Xuening Li; Hongcheng Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-17       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.